Abstract
Although children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8 mg/kg on day 1 and bendamustine 90–120 mg/m2 on days 2 and 3. At the end of treatment, the overall response rate was 81%. The 3-year overall and progression-free survivals are 78.1% and 67%, respectively.
Original language | English |
---|---|
Pages (from-to) | 1-9 |
Number of pages | 9 |
Journal | PEDIATRIC BLOOD & CANCER |
Volume | 69 |
DOIs | |
Publication status | Published - 2022 |
Keywords
- brentuximab vedotin
- Hodgkin lymphoma
- relapse
- pediatric
- refractory
- immunotherapy